comparemela.com

Crossject News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Crossject reports audited financial results for 2023

Dijon, France April 25, 2024 Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency.

Natasha drapeauSophie baumontUs biomedical advanced researchDevelopment authorityResearch tax creditCohesion bureauFrance aprilAdvanced researchParis stock exchange alcj

Crossject to host a business briefing on commercial

Dijon, France, February 1, 2024 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free.

Sophie baumontNatasha drapeauPatrick alexandreDevelopment authorityCohesion bureauBiomedical advanced researchSyneos healthExecutive chairmanOlivier gireSpecialty pharmaAdvanced researchParis stock exchange alcjCommercial strategyEpileptic seizuresTrat 233 gie commercialeRises 233 pileptiques

Crossject to present at Biotech Showcase on January 9 at

Press Release Crossject to present at Biotech Showcase on January 9 at 16:30 PT Dijon, France, January 9, 2024 Crossject (ISIN: FR0011716265;.

San franciscoUnited statesSophie baumontNatasha drapeauDevelopment authorityCohesion bureauBiomedical advanced researchBiotech showcaseBallroom levelAdvanced researchParis stock exchange alcjInvestor eventBiotech showcase conference

Crossject signs ZEPIZURE® commercialization agreement for

Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner,.

United kingdomNew zealandPatrick alexandreNatasha drapeauSophie baumontBiomedical advanced researchUs biomedical advanced researchCohesion bureauDevelopment authorityAdvanced researchParis stock exchange alcjCommercialization agreementElf injection systemCcord de commercialisationUto injecteurs33 pilepsie

Crossject reports financial results and business highlights

Press Release Crossject reports financial results and business highlights for first half of 2023 Strong progress in bringing drugs for use in.

New zealandFrance generalSophie baumontDaniel teperPatrick alexandreDaniel teperasNatasha drapeauDevelopment authorityFrench ministry of armed forces ministUs biomedical advanced researchCohesion bureauBiomedical advanced researchand development authoritySaclay universityHuman servicesAdministration for strategic preparednessFrench health agency

vimarsana © 2020. All Rights Reserved.